1. MF59-aQIV looks economically persuasive in Korea and Taiwan — but the price assumptions do a lot of the work This modelling study assessed the cost-effectiveness of MF59-adjuvanted quadrivalent influenza vaccine (aQIV) for adults aged 65 years and older in South Korea and Taiwan using a static decision-tree framework from payer and societal perspectives over one influenza season. The model compared aQIV with standard-dose QIV (SD-QIV) and high-dose QIV (HD-QIV), incorporating country-specific demography, attack rates, healthcare utilization, complication costs, and relative vaccine effectiveness assumptions. Versus SD-QIV, aQIV was projected to avert 71,352 symptomatic influenza cases, 5,443 hospitalizations, and 1,275 deaths in South Korea, and 13,530 symptomatic cases, 819 hospitalizations, and 140 deaths in Taiwan. The incremental cost-effectiveness ratios from the payer perspective were US$2,200/QALY in South Korea and US$6,798/QALY in Taiwan, both below the authors’ GDP-based willingness-to-pay thresholds. Against HD-QIV, aQIV was modelled as cost-saving in both countries, largely because the assumed purchase...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
